The enforcement timeline
The FDA's crackdown on GLP-1 telehealth marketing has been the most aggressive regulatory action in the compounding space in decades. Here's what happened and when.
September 2025: The FDA issued over 55 warning letters to online sellers of compounded GLP-1 medications, citing misleading direct-to-consumer advertising. At the time, many in the industry viewed it as "compliance theater" — warnings without teeth.
February 2026: HHS General Counsel announced a referral of Hims & Hers Health to the Department of Justice, signaling escalation beyond warning letters. The same month, the FDA announced steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products.
March 3, 2026: The FDA issued 30 more warning letters to telehealth companies — the second major wave. FDA Commissioner Makary stated: "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action."
March 9, 2026: Novo Nordisk and Hims & Hers announced a partnership: Hims will offer branded Novo Nordisk GLP-1 products while ceasing most advertising of compounded alternatives. The lawsuit was dismissed.
What the violations actually say
The FDA's warning letters primarily cite two categories of violations. First, claims implying compounded GLP-1 products are equivalent or comparable to FDA-approved medications like Wegovy or Zepbound. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality — and marketing them as if they were violates federal drug labeling laws. Second, telehealth branding that masks the actual compounding pharmacy, creating what the FDA calls "sourcing opacity" — making it impossible for patients to know where their medication actually comes from.
Companies were given 15 business days to correct violations after receiving a warning letter.
What this means for patients
If you're currently using a compounded GLP-1 medication from a telehealth provider, don't panic. A warning letter to your provider means the FDA found marketing compliance issues — not necessarily that your medication is unsafe. However, it should prompt you to verify your provider's compounding pharmacy credentials independently, understand that compounded medications are not equivalent to FDA-approved products (regardless of what the provider's marketing said), and monitor whether your provider makes corrections in response to the warning.
If your provider received a warning letter and hasn't corrected the cited violations, or continues to make the same misleading claims, consider that a significant red flag about their overall compliance culture.
How to check if your provider received a warning letter
The FDA publishes all warning letters on its website at fda.gov. Search for the company name in the Warning Letters database. You can also search by product type or date range to find GLP-1-specific enforcement actions. The full text of each warning letter is publicly available, including the specific violations cited and the evidence the FDA found.